Molecular markers and bladder carcinoma: Schistosomal and non-schistosomal.

Autor: Shaker OG; Medical Biochemistry Department, Faculty of Medicine, Cairo University, Egypt., Hammam OA, El Leithy TR, El Ganzoury H, Wishahi MM, Mikhailidis DP
Jazyk: angličtina
Zdroj: Clinical biochemistry [Clin Biochem] 2011 Feb; Vol. 44 (2-3), pp. 237-44. Date of Electronic Publication: 2010 Oct 08.
DOI: 10.1016/j.clinbiochem.2010.09.028
Abstrakt: Objectives: Detection of telomeric repeat amplification protocol (TRAP) activity, the human telomerase reverse transcriptase (hTERT), tumor suppressor gene (p53) and proliferating marker (MIB-1) in bladder specimens.
Design and Methods: Specimens were obtained from 85 patients and 10 controls. TRAP technique and immunohistochemistry (IHC) method were performed.
Results: TRAP activity, hTERT, p53 and MIB1 were detected in 62.4%, 65.9%, 57.6% and 62.4% of all 85 patient cases, respectively. TRAP activity was detected in 75% of schistosomal urothelial carcinoma, 100% in schistosomal squamous cell carcinoma (SQCC) and 71.4% in non-schistosomal urothelial carcinoma. hTERT protein was detected in schistosomal urothelial carcinoma (83.3%), 93.3% in schistosomal SQCC and 75.7% in non-schistosomal urothelial carcinoma.
Conclusions: TRAP and hTERT are useful for the detection of telomerase with special emphasis on their role in the detection of schistosomal-associated bladder cancer. Correlation of TRAP and hTERT protein with MIB1 and p53 reveals the importance of telomerase as a new marker in cancer bladder.
(Copyright © 2010 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: